Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.

Literature DB >> 23165468

Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.

Leah E Lim¹, Catherine Vilchèze, Carol Ng, William R Jacobs, Santiago Ramón-García, Charles J Thompson.

Abstract

Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis. Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2012 PMID： 23165468 PMCID： PMC3553693 DOI： 10.1128/AAC.01696-12

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

25 in total

1. Synthesis and biological evaluation of novel 4"-alkoxy avermectin derivatives.

Authors: Kenichiro Nagai; Kazuro Shiomi; Toshiaki Sunazuka; Achim Harder; Andreas Turberg; Satoshi Omura
Journal: Bioorg Med Chem Lett Date: 2004-08-16 Impact factor: 2.823

Review 2. The life and times of ivermectin - a success story.

Authors: Satoshi Omura; Andy Crump
Journal: Nat Rev Microbiol Date: 2004-12 Impact factor: 60.633

Review 3. Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors: David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal: Nat Rev Drug Discov Date: 2006-12-08 Impact factor: 84.694

Review 4. The pharmacokinetics and interactions of ivermectin in humans--a mini-review.

Authors: Aránzazu González Canga; Ana M Sahagún Prieto; M José Diez Liébana; Nélida Fernández Martínez; Matilde Sierra Vega; Juan J García Vieitez
Journal: AAPS J Date: 2008-01-25 Impact factor: 4.009

5. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Authors: Santiago Ramón-García; Carol Ng; Hilary Anderson; Joseph D Chao; Xingji Zheng; Tom Pfeifer; Yossef Av-Gay; Michel Roberge; Charles J Thompson
Journal: Antimicrob Agents Chemother Date: 2011-05-16 Impact factor: 5.191

6. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis.

Authors: S Foongladda; D Roengsanthia; W Arjrattanakool; C Chuchottaworn; A Chaiprasert; S G Franzblau
Journal: Int J Tuberc Lung Dis Date: 2002-12 Impact factor: 2.373

7. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method.

Authors: R Gomez-Flores; S Gupta; R Tamez-Guerra; R T Mehta
Journal: J Clin Microbiol Date: 1995-07 Impact factor: 5.948

8. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors: Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191

Review 9. The avermectins: A new family of antiparasitic agents.

Authors: I K Hotson
Journal: J S Afr Vet Assoc Date: 1982-06 Impact factor: 1.474

10. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors: Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal: Nat Commun Date: 2010-08-24 Impact factor: 14.919

35 in total

1. Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro.

Authors: Lais Pessanha de Carvalho; Thaisa Lucas Sandri; Edésio José Tenório de Melo; Rolf Fendel; Peter G Kremsner; Benjamin Mordmüller; Jana Held
Journal: Antimicrob Agents Chemother Date: 2019-07-25 Impact factor: 5.191

2. Isolation and identification of new macrocyclic lactones from a genetically engineered strain Streptomyces bingchenggensis BCJ60.

Authors: Jiansong Li; Shaoyong Zhang; Hui Zhang; Haiyan Wang; Ji Zhang; Anliang Chen; Jidong Wang; Wensheng Xiang
Journal: J Antibiot (Tokyo) Date: 2016-10-26 Impact factor: 2.649

Review 3. Advances in the development of new tuberculosis drugs and treatment regimens.

Authors: Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal: Nat Rev Drug Discov Date: 2013-05 Impact factor: 84.694

4. Effects of Fenbendazole-impregnated Feed and Topical Moxidectin during Quarantine on the Gut Microbiota of C57BL/6 Mice.

Authors: Scott W Korte; Craig L Franklin; Rebecca A Dorfmeyer; Aaron C Ericsson
Journal: J Am Assoc Lab Anim Sci Date: 2018-05-01 Impact factor: 1.232

5. Anthelmintic Therapy Modifies the Systemic and Mycobacterial Antigen-Stimulated Cytokine Profile in Helminth-Latent Mycobacterium tuberculosis Coinfection.

Authors: Rajamanickam Anuradha; Saravanan Munisankar; Yukthi Bhootra; Chandrakumar Dolla; Paul Kumaran; Thomas B Nutman; Subash Babu
Journal: Infect Immun Date: 2017-03-23 Impact factor: 3.441